X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1315) 1315
Newsletter (292) 292
Publication (146) 146
Book Review (12) 12
Magazine Article (10) 10
Newspaper Article (9) 9
Book Chapter (6) 6
Dissertation (3) 3
Conference Proceeding (2) 2
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
ranolazine (1573) 1573
humans (620) 620
index medicus (604) 604
cardiac & cardiovascular systems (450) 450
animals (372) 372
male (323) 323
piperazines - therapeutic use (283) 283
female (257) 257
angina pectoris (230) 230
pharmacology & pharmacy (230) 230
research (220) 220
piperazines - pharmacology (211) 211
acetanilides - therapeutic use (201) 201
atrial fibrillation (189) 189
angina pectoris - drug therapy (174) 174
care and treatment (172) 172
treatment outcome (168) 168
late sodium current (167) 167
analysis (166) 166
acetanilides - pharmacology (164) 164
ischemia (160) 160
drug therapy (146) 146
cardiovascular (145) 145
heart (141) 141
enzyme inhibitors - therapeutic use (138) 138
aged (137) 137
angina (136) 136
middle aged (135) 135
acetanilides (134) 134
electrocardiography (117) 117
antianginal agent (113) 113
arrhythmia (107) 107
sodium channel blockers - pharmacology (107) 107
heart failure (104) 104
arrhythmias (102) 102
cardiac patients (102) 102
piperazines - administration & dosage (101) 101
medical research (97) 97
cardiology (95) 95
reports (95) 95
rats (94) 94
medicine, experimental (92) 92
cardiovascular agents - therapeutic use (88) 88
article (87) 87
atrial fibrillation - drug therapy (85) 85
dose-response relationship, drug (85) 85
abridged index medicus (84) 84
myocytes, cardiac - drug effects (83) 83
action potentials - drug effects (81) 81
sodium channel blockers - therapeutic use (80) 80
anti-arrhythmia drugs (79) 79
anti-arrhythmia agents - pharmacology (78) 78
acetanilides - administration & dosage (76) 76
diabetes (75) 75
disease models, animal (75) 75
rabbits (75) 75
exercise tolerance (74) 74
piperazines - adverse effects (74) 74
anti-arrhythmia agents - therapeutic use (73) 73
dosage and administration (73) 73
drugs (73) 73
enzyme inhibitors - pharmacology (73) 73
ranolazine - therapeutic use (73) 73
myocardial ischemia - drug therapy (71) 71
coronary heart disease (70) 70
chronic angina (69) 69
chronic disease (68) 68
inhibition (68) 68
sodium - metabolism (68) 68
pharmacology (67) 67
amlodipine (66) 66
long-qt syndrome (66) 66
randomized controlled-trial (66) 66
chronic stable angina (65) 65
myocytes, cardiac - metabolism (64) 64
risk factors (64) 64
coronary artery disease (63) 63
electrophysiology (63) 63
time factors (63) 63
acetanilides - adverse effects (62) 62
amiodarone (62) 62
acute coronary syndromes (60) 60
atrial-fibrillation (60) 60
double-blind method (60) 60
physiology (60) 60
physiological aspects (59) 59
internal medicine (58) 58
peripheral vascular disease (58) 58
repolarization (58) 58
biological products industry (57) 57
drug therapy, combination (57) 57
myocardial ischemia (57) 57
atrial fibrillation - physiopathology (56) 56
clinical trials (56) 56
double-blind (56) 56
medicine & public health (55) 55
antiarrhythmic drugs (54) 54
heart rate - drug effects (54) 54
sodium channels - metabolism (54) 54
universities and colleges (54) 54
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1559) 1559
German (24) 24
Spanish (16) 16
Italian (13) 13
Russian (5) 5
Chinese (4) 4
French (4) 4
Japanese (3) 3
Polish (3) 3
Czech (1) 1
Danish (1) 1
Korean (1) 1
Portuguese (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Neuroscience Letters, ISSN 0304-3940, 08/2012, Volume 524, Issue 2, p. 101
a* Threshold tracking can non-invasively provide data on axonal membrane properties. a* Increased persistent Na.sup.+ current (Na.sub.p) is related to... 
Ranolazine
Journal Article
Heart Rhythm, ISSN 1547-5271, 11/2009, Volume 6, Issue 11, p. 1625
Ranolazine is an antianginal drug that inhibits the cardiac late Na.sup.+ current (I.sub.Na). The selectivity of ranolazine to block late I.sub.Na relative to... 
Ranolazine
Journal Article
Biophysical Journal, ISSN 0006-3495, 01/2015, Volume 108, Issue 2, pp. 195a - 196a
Journal Article
Journal of the American College of Cardiology, ISSN 0735-1097, 03/2004, Volume 43, Issue 5, pp. A128 - A128
Journal Article
Journal of Cellular Physiology, ISSN 0021-9541, 07/2019, Volume 234, Issue 7, pp. 11587 - 11601
Cardiac hypertrophy and heart failure are characterized by increased late sodium current and abnormal Ca handling. Ranolazine, a selective inhibitor of the... 
Heart failure | ranolazine | transient | hypertrophy
Journal Article
Neuroscience Letters, ISSN 0304-3940, 06/2012, Volume 518, Issue 1, p. 36
a* Threshold tracking can non-invasively provide axonal membrane properties. a* Persistent Na.sup.+ current (Na.sub.p) is related to neurodegeneration and... 
Cyanides | Ranolazine
Journal Article
Journal of Pharmaceutical Sciences and Research, 02/2017, Volume 9, Issue 2, pp. 145 - 149
Journal Article
Journal Article
Bioorganic & Medicinal Chemistry Letters, ISSN 0960-894X, 07/2016, Volume 26, Issue 13, pp. 3202 - 3206
Journal Article
Journal Article
Heart Rhythm, ISSN 1547-5271, 2015, Volume 12, Issue 5, pp. 872 - 878
Journal Article
Diabetes, Obesity and Metabolism, ISSN 1462-8902, 05/2016, Volume 18, Issue 5, pp. 463 - 474
Aim To report the results of two phase III trials assessing the efficacy of ranolazine for glycaemic control in patients with type 2 diabetes on metformin or... 
clinical trial | antidiabetic drug | glycaemic control | type 2 diabetes | randomized trial | Type 2 diabetes | Clinical trial | Randomized trial | Antidiabetic drug | Glycaemic control | Ranolazine - adverse effects | Ranolazine - pharmacokinetics | Metformin - therapeutic use | Ranolazine - therapeutic use | Cardiovascular Diseases - prevention & control | Humans | Middle Aged | Male | Metformin - adverse effects | Hypoglycemia - prevention & control | Glycated Hemoglobin A - antagonists & inhibitors | Hypoglycemic Agents - blood | Drug Therapy, Combination - adverse effects | Drug Interactions | Sodium Channel Blockers - adverse effects | Sodium Channel Blockers - therapeutic use | Female | Sulfonylurea Compounds - blood | Sulfonylurea Compounds - pharmacokinetics | Hypoglycemia - chemically induced | Drug Resistance | Metformin - blood | Hypoglycemic Agents - therapeutic use | Sodium Channel Blockers - blood | Hyperglycemia - prevention & control | Ranolazine - blood | Hypoglycemic Agents - pharmacokinetics | Double-Blind Method | Metformin - pharmacokinetics | Sulfonylurea Compounds - therapeutic use | Sulfonylurea Compounds - adverse effects | Diabetes Mellitus, Type 2 - blood | Aged | Cardiovascular Diseases - chemically induced | Diabetes Mellitus, Type 2 - drug therapy | Drug Monitoring | Sodium Channel Blockers - pharmacokinetics | Hypoglycemic Agents - adverse effects | Glycosylated hemoglobin | Glimepiride | Care and treatment | Diabetes therapy | Confidence intervals | Diabetes | Clinical trials | Hemoglobin | Metformin | Diabetes mellitus
Journal Article
European Journal of Heart Failure, ISSN 1388-9842, 04/2014, Volume 16, Issue 4, pp. 358 - 366
Aims Doxorubicin is widely used against cancer; however, it can produce heart failure (HF). Among other hallmarks, oxidative stress is a major contributor to... 
Doxorubicin cardiotoxicity • Ranolazine • Heart failure • Oxidative stress • Na+ | Doxorubicin cardiotoxicity • Ranolazine • Heart failure • Oxidative stress • Na | Heart failure | Oxidative stress | CARDIAC & CARDIOVASCULAR SYSTEMS | MANAGEMENT | MYOCYTES | NITROSATIVE STRESS | ISOLATED RAT HEARTS | CARDIOTOXICITY | EUROPEAN-SOCIETY | Ranolazine | DIASTOLIC DYSFUNCTION | Doxorubicin cardiotoxicity | CALCIUM | Na+ | HEART-FAILURE ASSOCIATION | INHIBITOR | Antibiotics, Antineoplastic - toxicity | Reactive Oxygen Species - metabolism | Cardiotoxicity - diagnostic imaging | Ventricular Dysfunction, Left - chemically induced | Atrial Natriuretic Factor - genetics | Reverse Transcriptase Polymerase Chain Reaction - methods | Ultrasonography | Acetanilides - therapeutic use | Real-Time Polymerase Chain Reaction | Cardiotoxicity - prevention & control | Blotting, Western - methods | Natriuretic Peptide, Brain - genetics | Myocytes, Cardiac - cytology | Mice, Inbred C57BL | RNA, Messenger - genetics | Oxidative Stress - genetics | Piperazines - therapeutic use | Enzyme Inhibitors - therapeutic use | Doxorubicin - toxicity | Sodium - blood | Ventricular Dysfunction, Left - prevention & control | Ventricular Dysfunction, Left - metabolism | Matrix Metalloproteinase 2 - genetics | Poly(ADP-ribose) Polymerases - metabolism | Animals | Connective Tissue Growth Factor - genetics | Mice | Oxidative Stress - drug effects
Journal Article